世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

免疫腫瘍学の取引動向 2011-2015年

Immuno-Oncology Deal Trends, 2011–15

 

出版社 出版年月電子版価格 ページ数
Datamonitor Healthcare
データモニターヘルスケア
2016年3月US$5,000
ベーシックライセンス
58

サマリー

このレポートは免疫腫瘍学の取引動向を調査したレポートです。免疫腫瘍学の取引形成の過去5年間の規模や金額などを掲載しています。

Report Details

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups’ deal volume in immuno-oncology has grown over sevenfold from 2011 to 2015.

More than 50% of the immuno-oncology deals between 2011 and 2015 involved testing combinations that may eventually address previously unresponsive patients and/or additional tumor types. Combination agreements are structured differently to traditional licensing deals and are often pre-competitive in nature, early stage, and involve only one or two single studies.

This report addresses the following questions:
• What is the growth of immuno-oncology deal-making over the last five years in volume and dollar value, and how does that compare with overall oncology deal-making?
• Who are the top players in immuno-oncology deal-making, and what were the structures of their key deals?
• Which solid and hematological tumor indications and anticancer immunotherapy targets are most involved immuno-oncology deals?
• What strategies are being implemented by some of the most influential companies in immuno-oncology?

 



目次

EXECUTIVE SUMMARY
IMMUNO-ONCOLOGY: A BRIEF INTRODUCTION
1.  Immuno-oncology has sparked multiple industry, academic, and government initiatives,
2. Bibliography

KEY TRENDS IN IMMUNO-ONCOLOGY DEAL-MAKING
3.  Immuno-oncology deal volume has rapidly increased,
4. Bristol-Myers Squibb and Merck & Co were the top immuno-oncology dealmakers,
5. Immuno-oncology represented most of the overall oncology deal value,
6. Solid tumors, especially lung cancer and melanoma, led immuno-oncology deals,
7. Non-Hodgkin's lymphoma and myeloma decreasing in overall share of deals,
8. PD-L1/PD-1 dominated immuno-oncology deals,
9. Immuno-oncology targets vary across indications,
10. Bibliography

IMMUNO-ONCOLOGY COMBINATIONS: COLLABORATIVE EFFORTS
11. Combinations are the driving force in immuno-oncology deal-making,
12. Combination collaborations have unique characteristics,
13. Combination collaborations,
14. Bibliography

IMMUNO-ONCOLOGY DEAL-MAKING CASE STUDIES
15. AstraZeneca has high hopes for durvalumab in combinations and in hematological cancers,
16. Bristol-Myers Squibb aims to extend immuno-oncology leadership,
17. Celgene is trying to make an impact in hematological cancers,
18. GlaxoSmithKline looks to alternative immuno-oncology targets,
19. Merck & Co is banking on Keytruda combinations,
20. Roche's atezolizumab advances in bladder cancer, but combinations and non-PD-L1 targets are of importance,
21. Bibliography

APPENDIX
22. Scope,
23. Methodology

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る